Relmada Therapeutics, Inc.
RLMD
$0.39
-$0.0083-2.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -79.98M | -86.49M | -86.76M | -94.30M | -98.79M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.81M | 32.33M | 36.83M | 41.51M | 44.05M |
| Change in Net Operating Assets | -1.58M | 952.10K | 1.75M | 4.59M | 3.08M |
| Cash from Operations | -51.76M | -53.21M | -48.18M | -48.19M | -51.66M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.56M | 47.96M | 35.67M | 20.51M | 50.45M |
| Cash from Investing | 51.56M | 47.96M | 35.67M | 20.51M | 50.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 246.70K | 246.70K | 246.70K | 246.70K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -287.10K | -213.10K | -123.50K | -123.50K | -98.50K |
| Cash from Financing | -40.40K | 33.60K | 123.20K | 123.20K | -98.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -234.70K | -5.21M | -12.38M | -27.56M | -1.30M |